VRTX Relative Valuation
VRTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRTX is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for VRTX's competitors is 4.42, providing a benchmark for relative valuation. Vertex Pharmaceuticals Inc Corp (VRTX) exhibits a P/S ratio of 9.16, which is 107.17% above the industry average. Given its robust revenue growth of 2.96%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Vertex Pharmaceuticals Inc (VRTX) currently overvalued or undervalued?
What is Vertex Pharmaceuticals Inc (VRTX) fair value?
How does VRTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Vertex Pharmaceuticals Inc (VRTX) as of May 19 2025?
What is the current FCF Yield for Vertex Pharmaceuticals Inc (VRTX) as of May 19 2025?
What is the current Forward P/E ratio for Vertex Pharmaceuticals Inc (VRTX) as of May 19 2025?